<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100113</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-CPU-0004-1</org_study_id>
    <nct_id>NCT00100113</nct_id>
  </id_info>
  <brief_title>Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1</brief_title>
  <official_title>Study of Interactions Between GBR 12909 and Cocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess potential interactions between intravenous (IV)&#xD;
      cocaine and 3 doses of GBR 12909.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology&#xD;
      study that will assess the potential interactions between IV cocaine and 3 escalating oral&#xD;
      doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration&#xD;
      and if there are significant interactions between GBR 12909 treatment concurrent with IV&#xD;
      cocaine infusions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2004</start_date>
  <completion_date>June 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
  </primary_outcome>
  <enrollment>24</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBR 12909</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be within 20% ideal body weight and must weigh at least 45 kg.&#xD;
&#xD;
          -  Must understand the study procedures and provide written informed consent.&#xD;
&#xD;
          -  Must meet DSM-4 criteria and are non-treatment seeking at time of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Please contact study site for more information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Cunningham, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical Branch - Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U of Texas Medical Branch Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555 1031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>December 22, 2004</study_first_submitted>
  <study_first_submitted_qc>December 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2004</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <keyword>cocaine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vanoxerine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

